TITLE:
Biphasic Insulin Aspart 30 Therapy in Insulin-Naïve and Insulin-Experienced Patients with Type 2 Diabetes: Results from the Jordanian Subgroup of the A1chieve Study
AUTHORS:
Jihad Haddad, Fares H. Haddad, Rashad Nasser, Abdel-Ellah Al-Shudifat, Firas Abbas Annabi, Levent Sandalci, Moawia Al-Kilani
KEYWORDS:
Biphasic Insulin Aspart 30, Jordan, Type 2 Diabetes, A1chieve, Clinical Practice
JOURNAL NAME:
Journal of Diabetes Mellitus,
Vol.4 No.4,
November
27,
2014
ABSTRACT: Objective: To analyse the
safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in a
Jordanian subgroup of the 24-week, non-interventional A1chieve study. Methods:
A total of 509 Jordanian patients with type 2 diabetes (392 insulin-naive and
117 insulin-experienced) starting BIAsp30, alone or in combination with oral
glucose-lowering drugs, were included. Safety and effectiveness outcomes were
analysed over 24 weeks. Results: Patients had a mean age of 55.8 years, body
mass index of 28.8 kg/m2 and
diabetes duration of 9.4 years at baseline. Two serious adverse drug reactions
of hypoglycaemia were reported. The proportion of patients who reported major
hypoglycaemic events decreased (2.4% at baseline vs. 0.2% at Week 24, p =
0.0039). The proportion of patients reporting overall hypoglycaemia increased
marginally (6.3% at baseline vs. 9.9% at Week 24, p = 0.0378), primarily
attributed to a rise in minor and nocturnal hypoglycaemia reported in
insulin-naive patients. From baseline to Week 24, the mean ± SD glycated
haemoglobin A1c level decreased from 9.8% ± 1.4% to 7.4% ± 0.9% (p